查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703318

鈣通道阻斷劑市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、應用、配銷通路、地區和競爭細分，2020-2030 年

Calcium Channel Blockers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球鈣通道阻斷劑 (CCB) 市場價值為 160.2 億美元，預計在預測期內將呈現強勁成長，到 2030 年將以 6.20% 的複合年成長率擴張。

市場概覽
預測期 2026-2030
2024年市場規模 160.2億美元
2030年市場規模 230.4億美元
2025-2030 年複合年成長率 6.20%
成長最快的領域 二氫吡啶（DHP）
最大的市場 北美洲

受心血管疾病（CVD）盛行率不斷上升、高血壓發病率不斷上升以及老年人口不斷擴大的推動，該市場正在穩步成長。鈣通道阻斷劑在高血壓、心絞痛和某些心律不整的治療中發揮著至關重要的作用，在更廣泛的心血管治療領域中具有重要意義。

不斷增強的健康意識、處方藥取得管道的改善以及藥物配方技術的進步進一步支持了市場擴張。在新興經濟體中，政府支持的醫療保健計劃和私營部門的投資正在提高患者獲得高血壓治療的機會，從而加速對 CCB 的需求。

關鍵市場促進因素

心血管疾病負擔加重

主要市場挑戰

監管複雜性和核准延遲

主要市場趨勢

轉向個人化心血管治療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：鈣通道阻斷劑市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依藥物類型（二氫吡啶、苯烷基胺、苯並西平）
    • 依用途分類（心絞痛、高血壓、肥厚性心肌病變、心律不整、其他）
    • 按配銷通路（網上藥局、醫院藥局、零售藥局）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美鈣通道阻斷劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲鈣通道阻斷劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太鈣通道阻斷劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美鈣通道阻斷劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲鈣通道阻斷劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球鈣通道阻斷劑市場：SWOT 分析

第 14 章：競爭格局

  • Bayer AG
  • Sanofi Sa
  • Pfizer Inc
  • Lupin Pharmaceuticals, Inc.
  • Searle Ltd
  • Knoll Pharmaceuticals Co
  • GlaxoSmithKline Plc.
  • Aventis Inc
  • AstraZeneca PLC
  • Novartis AG.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17248

Global Calcium Channel Blockers (CCB) Market was valued at USD 16.02 billion in 2024 and is expected to exhibit strong growth over the forecast period, expanding at a CAGR of 6.20% through 2030.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 16.02 Billion
Market Size 2030USD 23.04 Billion
CAGR 2025-20306.20%
Fastest Growing SegmentDihydropyridine (DHP)
Largest MarketNorth America

This market is experiencing steady growth, driven by the increasing prevalence of cardiovascular diseases (CVDs), the rising incidence of hypertension, and the expanding geriatric population. Calcium channel blockers play a vital role in the treatment of high blood pressure, angina, and certain cardiac arrhythmias, maintaining their significance within the broader cardiovascular therapeutics landscape.

Market expansion is further supported by growing health awareness, improved access to prescription medications, and advancements in drug formulation technologies. In emerging economies, government-backed healthcare programs and private sector investments are enhancing patient access to hypertension treatments, accelerating demand for CCBs.

Key Market Drivers

Increasing Burden of Cardiovascular Diseases

The growing incidence of cardiovascular diseases is a major factor propelling the calcium channel blockers market. As CVDs remain the leading cause of death globally-responsible for approximately 17.9 million deaths annually-the need for effective treatments, such as calcium channel blockers, continues to rise.

Hypertension, a common risk factor for heart disease, often requires long-term pharmacological management. CCBs are among the most widely prescribed antihypertensive agents due to their proven effectiveness and tolerability. However, public health data reveals gaps in awareness and management: around 46% of adults with hypertension are undiagnosed, only 42% receive treatment, and just 21% achieve adequate control of their condition.

The persistent global rise in CVD cases is driving the need for chronic disease management, resulting in a sustained increase in prescriptions for CCBs. Public health initiatives, awareness campaigns, and improved screening programs are also enabling earlier diagnosis and intervention, thereby contributing to market growth.

Key Market Challenges

Regulatory Complexity and Approval Delays

Pharmaceutical companies operating in the calcium channel blockers market must navigate a complex regulatory landscape. Global and regional regulatory bodies impose stringent requirements to ensure drug safety and efficacy, which can pose significant challenges for market players.

The drug approval process-especially for novel or reformulated therapies-demands extensive clinical trials, long timelines, and substantial financial investment. Any unforeseen safety concerns during development can result in delays or additional regulatory scrutiny.

Furthermore, variability in regulatory guidelines across different geographies necessitates continuous adaptation and compliance efforts, potentially slowing down the pace of innovation and product launches in certain markets.

Key Market Trends

Shift Toward Personalized Cardiovascular Therapies

The rise of personalized medicine is reshaping cardiovascular care, including the administration of calcium channel blockers. Advances in genomics and pharmacogenomics are enabling more tailored treatment strategies, allowing clinicians to select the most appropriate drug and dosage based on a patient's genetic profile.

This individualized approach reduces the likelihood of adverse drug reactions and improves therapeutic outcomes, thereby enhancing both clinical effectiveness and patient satisfaction. As healthcare systems globally move toward precision medicine, the integration of pharmacogenomic insights into cardiovascular treatment regimens is expected to support long-term growth in the calcium channel blockers market.

Key Market Players

  • Bayer AG
  • Sanofi Sa
  • Pfizer Inc
  • Lupin Pharmaceuticals, Inc.
  • Searle Ltd
  • Knoll Pharmaceuticals Co
  • GlaxoSmithKline Plc.
  • Aventis Inc
  • AstraZeneca PLC
  • Novartis AG

Report Scope:

In this report, the Global Calcium Channel Blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Calcium Channel Blockers Market, By Drug Type:

  • Dihydropyridine
  • Phenylalkylamine
  • Benzothizepine

Calcium Channel Blockers Market, By Application:

  • Angina
  • Hypertension
  • Hypertrophic Cardiomyopathy
  • Arrhythmia
  • Others

Calcium Channel Blockers Market, By Distribution Channel:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Calcium Channel Blockers Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Calcium Channel Blockers Market.

Available Customizations:

Global Calcium Channel Blockers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Calcium Channel Blockers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Dihydropyridine, Phenylalkylamine, Benzothizepine)
    • 5.2.2. By Application (Angina, Hypertension, Hypertrophic Cardiomyopathy, Arrhythmia, Others)
    • 5.2.3. By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Calcium Channel Blockers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Calcium Channel Blockers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Calcium Channel Blockers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Calcium Channel Blockers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe Calcium Channel Blockers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Calcium Channel Blockers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Calcium Channel Blockers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Calcium Channel Blockers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Calcium Channel Blockers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Calcium Channel Blockers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Calcium Channel Blockers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Calcium Channel Blockers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Calcium Channel Blockers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Calcium Channel Blockers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Calcium Channel Blockers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Calcium Channel Blockers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. South America Calcium Channel Blockers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Calcium Channel Blockers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Calcium Channel Blockers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Calcium Channel Blockers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Calcium Channel Blockers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Calcium Channel Blockers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Calcium Channel Blockers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Calcium Channel Blockers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Calcium Channel Blockers Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Bayer AG
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Sanofi Sa
  • 14.3. Pfizer Inc
  • 14.4. Lupin Pharmaceuticals, Inc.
  • 14.5. Searle Ltd
  • 14.6. Knoll Pharmaceuticals Co
  • 14.7. GlaxoSmithKline Plc.
  • 14.8. Aventis Inc
  • 14.9. AstraZeneca PLC
  • 14.10.Novartis AG.

15. Strategic Recommendations

16. About Us & Disclaimer